Advanced

AJNR - American Journal of Neuroradiology

Published ahead of print on May 22, 2008
doi: 10.3174/ajnr.A1110

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bose, A. Search for Related Content PubMed PubMed Citation Articles by Bose, A.

The Penumbra System: A Mechanical Device for the Treatment of Acute Stroke due to Thromboembolism

A. Bose^a,h, H. Henkes^b, K. Alfke^c, W. Reith^d, T.E. Mayer^e, A. Berlis^f, V. Branca^g, S. Po Sit^h for the Penumbra Phase 1 Stroke Trial Investigators

^a Lenox Hill Hospital, New York, NY
^b Robert Janker Klinik, Bonn, Germany
^c University of Kiel Medical Center, Kiel, Germany
^d Universitätsklinikum des Saarlandes, Homburg/Saar, Germany
^e Universität München Klinikum, Munich, Germany
^f Universität Hospital, Freiburg, Germany
^g Ospedale Maggiore Milano, Milan, Italy
^h Penumbra Inc, San Leandro, Calif

View larger version (29K): [in this window] [in a new window]   Fig 1. Schematic diagram of the Penumbra device.

View larger version (43K): [in this window] [in a new window]   Fig 2. Angiographic illustration of a target vessel before (A) and after (B) treatment by the PS. This patient was a 66-year-old man who presented 3 hours from symptom onset with an NIHSS score of 24, which improved to 8 at 24 hours after revascularization by the PS. He continued to recover with a 30-day NIHSS score of 2 and an mRS of 1.

View larger version (15K): [in this window] [in a new window]   Fig 3. Subjects outcome based on baseline NIHSS scores.

View larger version (18K): [in this window] [in a new window]   Fig 4. A comparison of the observed and expected mortality rates for the entire study cohort and after stratification by location of the target vessel. The expected rates were derived from historical rates from the natural history of the disease reported in the literature, prorated to the proportion of target vessel locations treated in this study (see References 1–3).